Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have earned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $11.6667.

Several research analysts recently issued reports on ACRV shares. Weiss Ratings upgraded shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Jefferies Financial Group reissued a “buy” rating on shares of Acrivon Therapeutics in a research report on Monday, March 2nd. Finally, Wall Street Zen downgraded shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, March 1st.

Acrivon Therapeutics Price Performance

Shares of Acrivon Therapeutics stock opened at $1.41 on Thursday. The company has a 50-day moving average of $1.70 and a 200 day moving average of $1.88. The firm has a market cap of $60.35 million, a price-to-earnings ratio of -0.71 and a beta of 1.90. Acrivon Therapeutics has a 1 year low of $1.15 and a 1 year high of $3.56.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.49). On average, equities analysts anticipate that Acrivon Therapeutics will post -1.92 EPS for the current year.

Institutional Trading of Acrivon Therapeutics

A number of institutional investors have recently made changes to their positions in ACRV. Focus Partners Wealth purchased a new stake in shares of Acrivon Therapeutics during the 3rd quarter valued at about $36,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Acrivon Therapeutics during the 4th quarter valued at about $40,000. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Acrivon Therapeutics during the 4th quarter valued at about $44,000. Quadrature Capital Ltd purchased a new position in shares of Acrivon Therapeutics in the fourth quarter worth approximately $50,000. Finally, Invesco Ltd. purchased a new position in shares of Acrivon Therapeutics in the first quarter worth approximately $72,000. Hedge funds and other institutional investors own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.